A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age
Latest Information Update: 30 May 2025
At a glance
Most Recent Events
- 06 Mar 2025 Planned End Date changed from 12 Mar 2026 to 31 Jul 2025.
- 06 Mar 2025 Planned primary completion date changed from 12 Mar 2026 to 31 Jul 2025.
- 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.